Axsome Therapeutics, Inc. (AXSM) Stock

About Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc. is led by CEO Herriot Tabuteau, employs 1,220 people, headquartered in New York City, US, publicly traded since 2015.

Axsome Therapeutics, Inc. (AXSM) stock trades at $145.04 with a market capitalization of $7.60B. The stock is valued at a negative price-to-earnings (P/E) ratio of -49.17, reflecting a net loss over the last twelve months, price-to-book of 113.99, price-to-sales of 12.22. Over the past 52 weeks the stock has ranged between $117.30 and $260.19, and currently trades 44.3% below its 52-week high.

On profitability, Axsome Therapeutics, Inc. generates a return on equity (ROE) of -255.60% (negative, reflecting a net loss), return on capital employed of -62.64%, an operating margin of -24.80%, a net profit margin of -24.68%.

Axsome Therapeutics, Inc. by the numbers, 2016–2025

Between 2016 and 2025 Axsome Therapeutics, Inc. reported revenue of $0 rising to $638.0M. Compounded, revenue has grown —% a year over five years, 133.7% over three, 65.3% over the last twelve months. Net profit fell to $-183.0M.

The most recent net margin is -24.68%. On a trailing twelve-month basis to Jun '26, revenue is $776.0M and net profit $-192.0M.

Borrowings rose from $10.0M to $241.0M, cash from operations was $-93.0M in the latest year, positive in 0 of the last 10.

Return on equity has averaged -363.8% over five years, and was -207.9% in the most recent year.

The share price itself has compounded at 30.1% a year over five years, 41.5% over three, 103.4% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Axsome Therapeutics, Inc. (AXSM) — frequently asked questions